OMO-103
Advanced Solid Tumors
About Peptomyc
Peptomyc is a clinical-stage biotech developing a novel class of MYC inhibitors based on its proprietary Omomyc-derived mini-protein platform. Its lead asset, OMO-103, has demonstrated safety and early clinical activity in a Phase I trial, leading to the initiation of a Phase Ib trial in pancreatic cancer and a Phase II trial in osteosarcoma. The company is positioned as a trailblazer in targeting the historically 'undruggable' MYC transcription factor, with the potential to address a high unmet need across many cancer types.
View full company profileAbout Peptomyc
Peptomyc is a clinical-stage biotech developing a novel class of MYC inhibitors based on its proprietary Omomyc-derived mini-protein platform. Its lead asset, OMO-103, has demonstrated safety and early clinical activity in a Phase I trial, leading to the initiation of a Phase Ib trial in pancreatic cancer and a Phase II trial in osteosarcoma. The company is positioned as a trailblazer in targeting the historically 'undruggable' MYC transcription factor, with the potential to address a high unmet need across many cancer types.
View full company profileTherapeutic Areas
Other Advanced Solid Tumors Drugs
| Drug | Company | Phase |
|---|---|---|
| NT219 | Purple Biotech | Phase 1/2 |
| INDP-101 | Indaptus Therapeutics | Phase 1 |
| NST-101 (estimated) | Novastage Pharmaceuticals | Phase 1/2 |
| Meta10-TILs | Leman Biotech | Phase 1 |
| PM14 | PharmaMar | Phase 1/2 |
| Ecubectedin (PM54) | PharmaMar | Phase 1 |
| M8891 | Merck KGaA | Phase 1/2 |
| P-002 | Panacea Biotec | Phase 1/2 |
| Undisclosed kinase inhibitor | Tyligand Bioscience | Phase 1 |
| TYK-001 | TYK Medicines | Phase 1/2 |
| PT-112 | SciClone Pharmaceuticals | Phase 1 |
| AP-202 | Advance Pharmaceutical | Phase 1/2 |